Sacubitril/Valsartan in Clinical Practice: A Report of 2 Cases.
Following the results of the PARADIGM-HF trial, the European Society of Cardiology (ESC) guidelines recommend sacubitril/valsartan to replace ACE inhibitors in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy and who fit trial criteria. However, the optimal use of sacubitril/valsartan in clinical practice needs further investigation. We report here the cases of 2 patients with HFrEH successfully treated with sacubitril/valsartan in our daily practice. Both subjects presented multiple comorbidities and received an implantable cardioverter defibrillator in primary prevention. In both patients, therapy with sacubitril/valsartan led to prompt (30 days) amelioration of heart function, with a corresponding decrease in NHYA class and without any relevant safety issue.
['Cosentino|Eugenio|E|']
D000368:Aged D000613:Aminobutyrates D057911:Angiotensin Receptor Antagonists D001713:Biphenyl Compounds D015897:Comorbidity D017147:Defibrillators, Implantable D004338:Drug Combinations D006333:Heart Failure D006801:Humans D008297:Male D008875:Middle Aged D013318:Stroke Volume D013777:Tetrazoles D000068756:Valsartan
Sacubitril Valsartan Heart failure Reduced ejection fraction